IRTC iRhythm Technologies, Inc.
USHealthcareAs of 2026-07-09 13:44
Why IRTC matters now
iRhythm Technologies, Inc. (IRTC) is a US stock in Healthcare. The latest InvestLog snapshot shows $117.70 with -6.10% on the session and $3.87B in market capitalization; recent performance reads 1-month -8.07% and YTD -41.02%.
The latest financial table shown here is Q1 2026, with revenue of $199.4M, net income of $-13.9M, and EPS of $-0.43. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.5%.
The latest indexable market news headline is "Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $179.50; recent insider activity includes Blackford Quentin S. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
21.10
P/S
4.37
EV/EBITDA
311.86
DCF Value
$97.28
FCF Yield
0.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
71.0%
Operating Margin
-2.7%
Net Margin
-3.5%
ROE
-20.6%
ROA
-2.8%
ROIC
-2.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $199.4M | $-13.9M | $-0.43 |
| Q4 2025 | $208.9M | $5.6M | $0.17 |
| FY 2025 | $747.1M | $-44.6M | $-1.39 |
| Q3 2025 | $192.9M | $-5.2M | $-0.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$188.75
Target (Median)
$179.50
Target Range
$152.00 - $255.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.28
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.